Find where to buy products from UK suppliers, including: distributors, industrial manufacturers, wholesalers, raw ingredients, bulk supplies and finished goods for sale.
Search for products or services, then visit the suppliers website for prices, SDS or more information. You can also view suppliers in Australia, NZ or the USA.
| Product | Description | |
|---|---|---|
| 1-NA-PP1 | 1-NA-PP1 is a reversible, cell-permeable inhibitor of Src-family tyrosine kinases that have been mutated, by a single base substitution, to become 'analog sensitive' (as), as compared to the wild-type kinase. Group: Pharmaceutical. Alternative Names: 1-(Tert-Butyl)-3-(naphthalen-1-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine; 1-Naphthyl PP1. CAS No. 221243-82-9. Pack Sizes: 25 mg. Product ID: B2693-102805. Molecular formula: C19H19N5. Mole weight: 317.39. Custom synthesis is available. Send your inquiries for more information. |  London |
| 2-((3-Iodo-1H-indazol-6-yl)thio)-N-methylbenzamide | An impurity of Axitinib, a tyrosine kinase inhibitor used for the treatment of kidney cancer. Group: Pharmaceutical. Alternative Names: Benzamide, 2-[(3-iodo-1H-indazol-6-yl)thio]-N-methyl-. CAS No. 885126-34-1. Pack Sizes: 100 mg. Product ID: B2694-467100. Molecular formula: C15H12IN3OS. Mole weight: 409.25. Custom synthesis is available. Send your inquiries for more information. | London |
| 2-Amino-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide | 2-Amino-N-(2-chloro-6-methylphenyl)-5-thiazolecarboxamide, is a precursor in the synthesis of Dasatinib, a protein tyrosine kinase inhibitor, and also for 2-Amino-thiazole-5-carboxylic Acid Phenylamide Derivatives, used as potent and selective anti-tumor drugs. Group: Pharmaceutical. Alternative Names: 2-Amino-N-(2-chloro-6-methylphenyl)-5-thiazolecarboxamide. CAS No. 302964-24-5. Pack Sizes: 1mg;1g;10g. Product ID: NP3528. Molecular formula: C11H10ClN3OS. Mole weight: 267.73. Custom synthesis is available. Send your inquiries for more information. | London |
| 5,7-Dihydrox -4'-methoxyisoflavone | Biochanin A, an O-methylated isoflavone from Trifolium pratense, inhibits protein tyrosine kinase (PTK) of epidermal growth factor receptor with IC50 values of 91.5 μM. Uses: Anti-tumorigenesis, anti-oxidation, and anti-inflammatory. Group: Pharmaceutical. Alternative Names: Biochanin; Pratensol; olmelin; 4'-methyl Genistein; 4-methylGenistein; 5,7-dihydroxy-4'-Methoxyisoflavone; NSC 123538; NSC-123538; NSC123538. CAS No. 491-80-5. Pack Sizes: 5 g. Product ID: NP1827. Molecular formula: C16H12O5. Mole weight: 284.26. Custom synthesis is available. Send your inquiries for more information. | London |
| AAL-993 | AAL-993 is a VEGFR tyrosine kinase inhibitor that possesses dual inhibition of VEGFR signaling and HIF-1α expression through ERK inhibition without affecting Akt phosphorylation. Group: Pharmaceutical. Alternative Names: AAL 993; AAL993; 2-((4-pyridyl)methyl)amino-N-(3-(trifluoromethyl)phenyl)benzamide. CAS No. 269390-77-4. Pack Sizes: 1mg;1g;10g. Product ID: 269390-77-4. Molecular formula: C20H16F3N3O. Mole weight: 371.36. Custom synthesis is available. Send your inquiries for more information. | London |
| AC 220 dihydrochloride | AC 220 dihydrochloride is a potent and selective inhibitor of FMS-like tyrosine kinase-3 (FLT3) used for the treatment of AML. Uses: The treatment of aml. Group: Pharmaceutical. Alternative Names: AC 220 dihydrochloride; AC220 dihydrochloride; AC-220 dihydrochloride; Quizartinib dihydrochloride; 1-(5-tert-butyl-1,2-oxazol-3-yl)-3-[4-[6-(2-morpholin-4-ylethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl]urea dihydrochloride. CAS No. 1132827-21-4. Pack Sizes: 1mg;1g;10g. Product ID: 1132827-21-4. Molecular formula: C29H32N6O4S.2HCl. Mole weight: 633.59. Custom synthesis is available. Send your inquiries for more information. | London |
| AC480 | AC480, also known as BMS-599626, is an orally bioavailable inhibitor of the HER1, HER2 and HER4 tyrosine kinases (IC50 =22, 32 and 190 nM, respectively) with potential antineoplastic activity. BMS-599626 inhibits human epidermal growth factor receptors (HER) HER1, HER2 and HER4, thereby inhibiting the proliferation of tumor cells that overexpress these receptors. Group: Pharmaceutical. Alternative Names: BMS-599626; BMS 599626; BMS599626; AC 480; AC-480; Carbamic acid, N-[4-[[1-[(3-fluorophenyl)methyl]-1H-indazol-5-yl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]-, (3S)-3-morpholinylmethyl ester; (3S)-3-Morpholinylmethyl N-[4-[[1-[(3-fluorophenyl)methyl]-1H-indazol-5-yl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamate; Carbamic acid, [4-[[1-[(3-fluorophenyl)methyl]-1H-indazol-5-yl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]-, (3S)-3-morpholinylmethyl ester; N-[4-[[1-[(3-fluorophenyl)methyl]-1H-indazol-5-yl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]-carbamic acid, (3S)-3-morpholinylmethyl ester. CAS No. 714971-09-2. Pack Sizes: 1mg;1g;10g. Product ID: B0084-259278. Molecular formula: C27H27FN8O3. Mole weight: 530.55. Custom synthesis is available. Send your inquiries for more information. | London |
| Acalabrutinib | Acalabrutinib, also known as ACP-196, is an orally available inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. It inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. Group: Pharmaceutical. Alternative Names: ACP-196; ACP196; ACP 196; Acalabrutinib; 4-[8-amino-3-[(2S)-1-but-2-ynoylpyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl]-N-pyridin-2-ylbenzamide. CAS No. 1420477-60-6. Pack Sizes: 250 mg. Product ID: B0084-470855. Molecular formula: C26H23N7O2. Mole weight: 465.52. Custom synthesis is available. Send your inquiries for more information. | London |
| Acalabrutinib-[d4] | Acalabrutinib-[d4] is a labelled version of Acalabrutinib. Acalabrutinib, also known as ACP-196, is an orally available inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. It inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. Group: Pharmaceutical. Alternative Names: (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl-d4)benzamide; Acalabrutinib D4; Acalabrutinib-d4; 4-[8-Amino-3-[(2S)-1-(1-oxo-2-butyn-1-yl)-2-pyrrolidinyl]imidazo[1,5-a]pyrazin-1-yl]-N-2-pyridinylbenzamide-d4; ACP 196-d4; Calquence-d4. CAS No. 2699608-18-7. Pack Sizes: 5 mg. Product ID: BLP-003188. Molecular formula: C26H19D4N7O2. Mole weight: 469.53. Custom synthesis is available. Send your inquiries for more information. | London |
| AEE-788 | AEE-788 is an orally bioavailable multiple-receptor tyrosine kinase inhibitor. AEE788 inhibits phosphorylation of the tyrosine kinases of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and vascular endothelial growth factor receptor 2 (VEGF2), resulting in receptor inhibition, the inhibition of cellular proliferation, and induction of tumor cell and tumor-associated endothelial cell apoptosis. Group: Pharmaceutical. Alternative Names: AEE 788; AEE788; 6-[4-[(4-ethylpiperazin-1-yl)methyl]phenyl]-N-[(1R)-1-phenylethyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine. CAS No. 497839-62-0. Pack Sizes: 10 mg. Product ID: B0084-258485. Molecular formula: C27H32N6. Mole weight: 440.595. Custom synthesis is available. Send your inquiries for more information. | London |
| AG 126 | Tyrphostins are protein tyrosine kinase inhibitors developed to inhibit cell growth through blocking the activity of certain GFRK (growth factor receptor kinases). AG 126 selectively inhibits the phosphorylation of ERK1 and ERK2 at 25-50 μM. It also inhibits the production of TNF-α (tumor necrosis factor-α), attenuating signaling through NF-κB, the induced expression of COX-2 and iNOS, and the inflammatory response in animal models. AG 126 is a poor inhibitor of epidermal GFRK with IC50 of 450 μM and platelet-derived GFRK with IC50 > 100 μM. AG 126 may represent a new approach for the therapy of inflammation. Uses: Anti- inflammation. Group: Pharmaceutical. Alternative Names: AG126; AG-126; Tyrphostin AG 126; UNII-7YA4AMD1JC; Tyrphostin A 10; alpha-Cyano-(3-hydroxy-4-nitro)cinnamonitrile. CAS No. 118409-62-4. Pack Sizes: 100 mg. Product ID: B1370-195904. Molecular formula: C10H5N3O3. Mole weight: 215.16. Custom synthesis is available. Send your inquiries for more information. | London |
| AG-1557 | AG-1557 is an inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase. Group: Pharmaceutical. Alternative Names: AG-1557; AG 1557; AG1557; N-(3-Iodophenyl)-6,7-dimethoxyquinazolin-4-amine. CAS No. 189290-58-2. Pack Sizes: 50 mg. Product ID: B0084-284805. Molecular formula: C16H14IN3O2. Mole weight: 407.211. Custom synthesis is available. Send your inquiries for more information. | London |
| AG-879 | AG-879, a tyrphostin compound, is a dual EGFR/HER2 inhibitor that was administered together with androgen withdrawal therapy. It inhibits nerve growth factor (NGF)-dependent TrkA tyrosine phosphorylation in PC-12 cells (IC50 = ~40 μM), HER2-ErbB2 kinase in several breast and ovarian cancer cell lines (IC50 = ~0.5 μM), and the VEGF receptor FLK1 (IC50 = ~1 μM). Group: Pharmaceutical. Alternative Names: α-Cyano-(3,5-di-t-butyl-4-hydroxy)thiocinnamide. CAS No. 148741-30-4. Pack Sizes: 20 mg. Product ID: B0084-195953. Molecular formula: C18H24N2OS. Mole weight: 316.5. Custom synthesis is available. Send your inquiries for more information. | London |
| Apatinib mesylate | Apatinib mesylate is an orally bioavailable, small-molecule receptor tyrosine kinase inhibitor with potential antiangiogenic and antineoplastic activities. Apatinib selectively binds to and inhibits vascular endothelial growth factor receptor 2, which may inhibit VEGF-stimulated endothelial cell migration and proliferation and decrease tumor microvessel density. In addition, this agent mildly inhibits c-Kit and c-SRC tyrosine kinases. Uses: Antineoplastic agents. Group: Pharmaceutical. Alternative Names: YN968D1. CAS No. 1218779-75-9. Pack Sizes: 250 mg. Product ID: B2693-457664. Molecular formula: C25H27N5O4S. Mole weight: 493.58. Custom synthesis is available. Send your inquiries for more information. | London |
| Asciminib | Asciminib, also known as ABL-001, is a potent and selective allosteric Bcr-Abl inhibitor. Asciminib inhibits Ba/F3 cell growth with an IC50 of 0.25 nM. Uses: Tyrosine kinase inhibitors. Group: Pharmaceutical. Alternative Names: ABL-001; ABL 001; ABL001; N-[4-[chloro(difluoro)methoxy]phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide. CAS No. 1492952-76-7. Pack Sizes: 10 mg. Product ID: B0084-007699. Molecular formula: C20H18ClF2N5O3. Mole weight: 449.843. Custom synthesis is available. Send your inquiries for more information. | London |
| AT9283 | AT-9283 is a broad spectrum kinase inhibitor that potently inhibits Aurora A, Aurora B, JAK2, JAK3, and c-ABL (IC50= 3, 3, 1.2, 1.1, and 4 nM, respectively). It also potently (IC50 = <1 μM) inhibits serine/threonine kinases as well as receptor and non-receptor tyrosine kinases. Group: Pharmaceutical. Alternative Names: AT9283; AT 9283; AT-9283. CAS No. 896466-04-9. Pack Sizes: 10 mg. Product ID: B0084-100114. Molecular formula: C19H23N7O2. Mole weight: 381.43. Custom synthesis is available. Send your inquiries for more information. | London |
| AV-412 | AV-412 is a second-generation, orally bioavailable dual kinase inhibitor with potential antineoplastic activity. EGFR/HER2 inhibitor AV-412 binds to and inhibits the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor 2 (HER2), which may suppress tumor growth and angiogenesis, and tumor regression in EGFR/HER2-expressing tumors. This agent may be active against EGFR/HER2-expressing tumor cells that are resistant to first-generation kinase inhibitors. EGFR and HER2 are receptor tyrosine kinases that play major roles in tumor cell proliferation and tumor vascularization. Group: Pharmaceutical. Alternative Names: AV 412; AV412; N-[4-(3-chloro-4-fluoroanilino)-7-[3-methyl-3-(4-methylpiperazin-1-yl)but-1-ynyl]quinazolin-6-yl]prop-2-enamide. CAS No. 451492-95-8. Pack Sizes: 20 mg. Product ID: B0084-324573. Molecular formula: C27H28ClFN6O. Mole weight: 507.01. Custom synthesis is available. Send your inquiries for more information. | London |
| AVL-292 | AVL-292, also known as CC-292, is an orally bioavailable, selective inhibitor of Bruton's agammaglobulinemia tyrosine kinase (BTK), with potential antineoplastic activity. Upon administration, AVL-292 targets and covalently binds to BTK, thereby preventing its activity. Uses: Protein kinase inhibitors. Group: Pharmaceutical. Alternative Names: CC-292; CC292; CC 292; AVL292; AVL 292; spebrutinib. CAS No. 1202757-89-8. Pack Sizes: 1 g. Product ID: B2693-462475. Molecular formula: C22H22FN5O3. Mole weight: 423.44. Custom synthesis is available. Send your inquiries for more information. | London |
| Axitinib | Axitinib (AG013736) is a tyrosine kinase inhibitor developed by Pfizer. Axitinib is a tyrosine kinase inhibitor that blocks the activation of VEGFR1, VEGFR2, VEGFR3, c-kit, and PDGFRβ (IC50 = 1.2, 0.25, 0.29, 1.7, and 1.6 nM, respectively). It has been shown to significantly inhibit growth of breast cancer in animal (xenograft) models. Uses: Protein kinase inhibitors. Group: Pharmaceutical. Alternative Names: AG 013736; N-methyl-2-[[3-[(1E)-2-(2-pyridinyl)ethenyl]-1H-indazol-6-yl]thio]-benzamide; Inlyta. CAS No. 319460-85-0. Pack Sizes: 5 g. Product ID: NP3631. Molecular formula: C22H18N4OS. Mole weight: 386.5. Custom synthesis is available. Send your inquiries for more information. | London |
| Axitinib Impurity 2 | An impurity of Axitinib, a tyrosine kinase inhibitor used for the treatment of kidney cancer. Group: Pharmaceutical. Alternative Names: 2,2'-((6,6'-(2,4-Di(pyridin-2-yl)cyclobutane-1,3-diyl)bis(1H-indazole-6,3-diyl))bis(sulfanediyl))bis(N-methylbenzamide). CAS No. 1428728-83-9. Pack Sizes: 5 mg. Product ID: B2694-467092. Molecular formula: C44H36N8O2S2. Mole weight: 772.96. Custom synthesis is available. Send your inquiries for more information. | London |
| Axitinib sulfoxide | A major metabolite of Axitinib, a tyrosine kinase inhibitor used for the treatment of kidney cancer. Group: Pharmaceutical. Alternative Names: N-Methyl-2-[[3-[(1E)-2-(2-pyridinyl)ethenyl]-1H-indazol-6-yl]sulfinyl]-benzamide; Axitinib Impurity A. CAS No. 1347304-18-0. Pack Sizes: 10 mg. Product ID: B2694-467095. Molecular formula: C22H18N4O2S. Mole weight: 402.48. Custom synthesis is available. Send your inquiries for more information. | London |
| AZD-8931 | Sapitinib, also known as AZD-8931, is an erbB receptor tyrosine kinase inhibitor with potential antineoplastic activity. AZD8931 binds to and inhibits erbB tyrosine receptor kinases, which may result in the inhibition of cellular proliferation and angiogenesis in tumors expressing erbB. Group: Pharmaceutical. Alternative Names: AZD8931; AZD 8931; Momelotinib; Sapitinib. CAS No. 848942-61-0. Pack Sizes: 100 mg. Product ID: B0084-286313. Molecular formula: C23H25ClFN5O3. Mole weight: 473.933. Custom synthesis is available. Send your inquiries for more information. | London |
| Bemcentinib | Bemcentinib is a selective small molecule inhibitor of Axl kinase, which showed activity to blocks tumor spread and prolongs survival in models of metastatic breast cancer. The receptor tyrosine kinase Axl may play an important role in cancer progression, invasion, metastasis, drug resistance, and patient mortality. R428 inhibits Axl with low nanomolar activity and blocked Axl-dependent events, including Akt phosphorylation, breast cancer cell invasion, and proinflammatory cytokine production. Pharmacologic investigations revealed favorable exposure after oral administration such that R428-treated tumors displayed a dose-dependent reduction in expression of the cytokine granulocyte macrophage colony-stimulating factor and the epithelial-mesenchymal transition transcriptional regulator Snail. In support of an earlier study, R428 inhibited angiogenesis in corneal micropocket and tumor models. R428 administration reduced metastatic burden and extended survival in MDA-MB-231 intracardiac and 4T1 orthotopic (median survival, >80 days compared with 52 days; P < 0.05) mouse models of breast cancer metastasis. Additionally, R428 synergized with cisplatin to enhance suppression of liver micrometastasis. Our results show that Axl signaling regulates breast cancer metastasis at multiple levels in tumor cells and tumor stromal cells and that selective Axl blockade confers therapeutic value in prolonging survival of animals bearing metastÂ… | London |
| BLZ945 | BLZ945 is an orally active, potent and selective CSF-1R inhibitor, which inhibits CSF-1R activity with an IC50 of 1nM and is more than 1000-fold selective against its closest receptor tyrosine kinase homologs c-KIT and Platelet-derived Growth Factor Receptor beta (PDGFRb). Group: Pharmaceutical. Alternative Names: sotuletinib; BLZ 945; BLZ-945. CAS No. 953769-46-5. Pack Sizes: 50 mg. Product ID: B0084-463485. Molecular formula: C20H22N4O3S. Mole weight: 398.48. Custom synthesis is available. Send your inquiries for more information. | London |
| BMS-986195 | BMS-986195 is a Bruton's tyrosine kinase (BTK) inhibitor with IC50 of 0.1 nM. Group: Pharmaceutical. Alternative Names: Branebrutinib; BMS 986195; BMS986195. CAS No. 1912445-55-6. Pack Sizes: 200 mg. Product ID: B1370-057810. Molecular formula: C20H23FN4O2. Mole weight: 370.42. Custom synthesis is available. Send your inquiries for more information. | London |
| Brivanib | Brivanib is the hydrolyzed form of Brivanib alaninate, which is a vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor with potential antineoplastic activity. Brivanib strongly binds to and inhibits VEGFR2, a tyrosine kinase receptor expressed almost exclusively on vascular endothelial cells; inhibition of VEGFR2 may result in inhibition of tumor angiogenesis, inhibition of tumor cell growth, and tumor regression. Check for active clinical trials or closed clinical trials using this agent. Group: Pharmaceutical. Alternative Names: BMS540215; BMS-540215; BMS 540215. CAS No. 649735-46-6. Pack Sizes: 20 mg. Product ID: B0084-146707. Molecular formula: C19H19FN4O3. Mole weight: 370.37756. Custom synthesis is available. Send your inquiries for more information. | London |
| Brivanib alaninate | Brivanib alaninate is the alaninate ester of a vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor with potential antineoplastic activity. Brivanib strongly binds to and inhibits VEGFR2, a tyrosine kinase receptor expressed almost exclusively on vascular endothelial cells; inhibition of VEGFR2 may result in inhibition of tumor angiogenesis, inhibition of tumor cell growth, and tumor regression. Check for active clinical trials or closed clinical trials using this agent. Group: Pharmaceutical. Alternative Names: BMS-582664; BMS582664; BMS 582664. CAS No. 649735-63-7. Pack Sizes: 10 mg. Product ID: B2693-146708. Molecular formula: C22H24FN5O4. Mole weight: 441.45. Custom synthesis is available. Send your inquiries for more information. | London |
| Cediranib dihydrochloride | Cediranib (AZD-2171; tentative trade name Recentin) is a potent inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases.The drug is being developed by AstraZeneca as a possible anti-cancer chemotherapeutic agent for oral administration. Group: Pharmaceutical. Alternative Names: US brand name: Recentin. Foreign brand name: Recentin. Code name: AZD2171.AZD 2171; AZD-2171. CAS No. 288383-20-0. Pack Sizes: 50 mg. Product ID: B2693-065171. Molecular formula: C25H27FN4O3. Mole weight: 450.5. Custom synthesis is available. Send your inquiries for more information. | London |
| Cobimetinib | Cobimetinib (GDC-0973, RG7420) is a potent, orally available and highly selective MEK1 inhibitor with IC50 of 4.2 nM. It shows more than 100-fold selectively for MEK1 over MEK2 when tested against a panel of more than 100 serine-threonine and tyrosine kinases and showed no significant inhibition when tested against a panel of more than 100 of serine-threonine and tyrosine kinases. Group: Pharmaceutical. Alternative Names: XL518; GDC-0973; RG7420. CAS No. 934660-93-2. Pack Sizes: 25 mg. Product ID: B0084-460683. Molecular formula: C21H21F3IN3O2. Mole weight: 531.31. Custom synthesis is available. Send your inquiries for more information. | London |
| Dacomitinib | Dacomitinib, aslo known as PF-299 and PF-00299804; or PF299804, is an orally bioavailable, highly selective, second-generation small-molecule inhibitor of the pan-epidermal growth factor receptor (EGFR) family of tyrosine kinases (ErbB family) with potential antineoplastic activity. Dacomitinib specifically and irreversibly binds to and inhibits human EGFR subtypes, resulting in inhibition of proliferation and induction of apoptosis in EGFR-expressing tumor cells. EGFRs play major roles in tumor cell proliferation and tumor vascularization, and are often overexpressed or mutated in various tumor cell types. Group: Pharmaceutical. Alternative Names: dacomitinib; PF-00299804; PF00299804; PF 00299804; PF299804; PF-299804; PF 299804; PF-299; PF 299; PF299. CAS No. 1110813-31-4. Pack Sizes: 250 mg. Product ID: B0084-452473. Molecular formula: C24H25ClFN5O2. Mole weight: 469.945. Custom synthesis is available. Send your inquiries for more information. | London |
| Damnacanthal | Damnacanthal is a natural compound isolated from the fruit of Morinda citrifolia Linn. Damnacanthal acts as a potent and selective inhibitor of p56lck tyrosine kinase. It inhibits p56lck autophosphorylation with IC50 of 17 nM. Group: Pharmaceutical. Alternative Names: 1-Methoxy-2-formyl-3-hydroxy-9,10-anthraquinone; 3-Hydroxy-1-methoxyanthraquinone-2-aldehyde. CAS No. 477-84-9. Pack Sizes: 5 mg. Product ID: NP0889. Molecular formula: C16H10O5. Mole weight: 282.25. Custom synthesis is available. Send your inquiries for more information. | London |
| Dasatinib | Dasatinib, also known as BMS-354825, is an orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases. Dasatinib binds to and inhibits the growth-promoting activities of these kinases. Apparently because of its less stringent binding affinity for the BCR-ABL kinase, dasatinib has been shown to overcome the resistance to imatinib of chronic myeloid leukemia (CML) cells harboring BCR-ABL kinase domain point mutations. SRC-family protein-tyrosine kinases interact with variety of cell-surface receptors and participate in intracellular signal transduction pathways; tumorigenic forms can occur through altered regulation or expression of the endogenous protein and by way of virally-encoded kinase genes. Group: Pharmaceutical. Alternative Names: BMS-354825; BMS354825; BMS354825. CAS No. 302962-49-8. Pack Sizes: 25 g. Product ID: NP3264. Molecular formula: C22H26ClN7O2S. Mole weight: 488.01. Custom synthesis is available. Send your inquiries for more information. | London |
| Defactinib | Defactinib, also known as VS-6063 and PF-04554878, is an orally bioavailable, small-molecule focal adhesion kinase (FAK) inhibitor with potential antiangiogenic and antineoplastic activities. FAK inhibitor PF-04554878 inhibits FAK, which may prevent the integrin-mediated activation of several downstream signal transduction pathways, including ERK, JNK/MAPK and PI3K/Akt, thus inhibiting tumor cell migration, proliferation and survival. The tyrosine kinase FAK is , a signal transducer for integrins that is upregulated in many tumor cell types and is involved in tumor cell invasion, migration and proliferation. Group: Pharmaceutical. Alternative Names: N-methyl-4-((4-(((3-(N-methylmethylsulfonamido)pyrazin-2-yl)methyl)amino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)benzamide; VS6063; VS 6063; VS-6063; PF04554878; PF-04554878; PF 04554878; PF4554878; PF-4554878. CAS No. 1073154-85-4. Pack Sizes: 200 mg. Product ID: B0084-462762. Molecular formula: C20H21F3N8O3S. Mole weight: 510.496. Custom synthesis is available. Send your inquiries for more information. | London |
| Desmethyl Erlotinib | A metabolite of Erlotinib. Erlotinib is a tyrosine kinase inhibitor which acts on the epidermal growth factor receptor (EGFR), inhibiting EGFR-associated kinase activity. Group: Pharmaceutical. Alternative Names: 2-[[4-[(3-Ethynylphenyl)amino]-7-(2-methoxyethoxy)-6-quinazolinyl]oxy]ethanol. CAS No. 183321-86-0. Pack Sizes: 5 mg. Product ID: B2694-263407. Molecular formula: C21H21N3O4. Mole weight: 379.42. Custom synthesis is available. Send your inquiries for more information. | London |
| Dihydro-Axitinib | Dihydro-Axitinib is an impurity of Axitinib, a tyrosine kinase inhibitor used for the treatment of kidney cancer. Group: Pharmaceutical. CAS No. 1443118-73-7. Pack Sizes: 10 mg. Product ID: B1370-467094. Molecular formula: C22H20N4OS. Mole weight: 388.49. Custom synthesis is available. Send your inquiries for more information. | London |
| Dimethyl 3,3'-(((((2,2'-(piperazine-1,4-diyl)bis(acetyl))bis(methylazanediyl))bis(4,1-phenylene))bis(azanediyl))bis(phenylmethanylylidene))(3Z,3'E)-bis(2-oxoindoline-6-carboxylate) | An impurity of Nintedanib, a receptor tyrosine kinase (RTK) inhibitor that binds to vascular endothelial growth factor receptor, fibroblast growth factor receptor and platelet derived growth factor receptor. Nintedanib is used as a medication for the treatment of idiopathic pulmonary fibrosis. Group: Pharmaceutical. Alternative Names: Nintedanib Impurity 50. CAS No. 2410284-90-9. Pack Sizes: 1 mg. Product ID: B2694-478193. Molecular formula: C56H52N8O8. Mole weight: 965.08. Custom synthesis is available. Send your inquiries for more information. | London |
| Ehp-inhibitor-1 | Ehp-inhibitor-1 is an Eph family tyrosine kinase inhibitor targeting Eph receptors. Study indicated that inhibition of Eph receptors results in an increase in glucose-stimulated insulin secretion from mouse and human pancreatic islets. Group: Pharmaceutical. Alternative Names: 6-(3-methoxyphenyl)-3-pyridin-3-ylpyrazolo[1,5-a]pyrimidin-7-amine. CAS No. 861249-59-4. Pack Sizes: 50 mg. Product ID: B0084-284759. Molecular formula: C18H15N5O. Mole weight: 317.352. Custom synthesis is available. Send your inquiries for more information. | London |
| Ehp-inhibitor-2 | Ehp-inhibitor-2 is an Eph family tyrosine kinase inhibitor targeting Eph receptors. Study indicated that inhibition of Eph receptors results in an increase in glucose-stimulated insulin secretion from mouse and human pancreatic islets. Group: Pharmaceutical. Alternative Names: 3-(7-amino-3-(pyridin-3-yl)pyrazolo[1,5-a]pyrimidin-6-yl)phenol. CAS No. 861249-77-6. Pack Sizes: 50 mg. Product ID: B0084-284760. Molecular formula: C17H13N5O. Mole weight: 303.325. Custom synthesis is available. Send your inquiries for more information. | London |
| ENMD-2076 | ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor with a unique kinase selectivity profile and multiple mechanisms of action. ENMD-2076 has been shown to inhibit a distinct profile of angiogenic tyrosine kinase targets in addition to the Aurora A kinase. Aurora kinases are key regulators of mitosis (cell division), and are often over-expressed in human cancers. ENMD-2076 also targets the VEGFR, Flt-3 and FGFR3 kinases which have been shown to play important roles in the pathology of several cancers. ENMD-2076 has shown promising activity in Phase 1 clinical trials in solid tumor cancers, leukemia, and multiple myeloma. ENMD-2076 is currently in a Phase 2 trial for ovarian cancer, and preclinical and clinical activities are ongoing in assessing the compound's applicability for other forms of cancer. Group: Pharmaceutical. Alternative Names: ENMD-2076; ENMD 2076; ENMD2076. CAS No. 934353-76-1. Pack Sizes: 50 mg. Product ID: B2693-156198. Molecular formula: C21H25N7. Mole weight: 375.47. Custom synthesis is available. Send your inquiries for more information. | London |
| Erlotinib-3-vinyl Hydrochloride | A metabolite of Erlotinib. Erlotinib is a tyrosine kinase inhibitor which acts on the epidermal growth factor receptor (EGFR), inhibiting EGFR-associated kinase activity. Group: Pharmaceutical. Alternative Names: 6,7-Bis(2-methoxyethoxy)-N-(3-vinylphenyl)quinazolin-4-amine hydrochloride; 4-Quinazolinamine, N-(3-ethenylphenyl)-6,7-bis(2-methoxyethoxy)-, hydrochloride (1:1). CAS No. 1624294-38-7. Pack Sizes: 25 mg. Product ID: B1370-173396. Molecular formula: C22H26ClN3O4. Mole weight: 431.91. Custom synthesis is available. Send your inquiries for more information. | London |
| Erlotinib-[d6] Hydrochloride | Erlotinib-[d6] Hydrochloride is the labelled analogue of Erlotinib. Erlotinib is a tyrosine kinase inhibitor which acts on the epidermal growth factor receptor (EGFR), inhibiting EGFR-associated kinase activity. Erlotinib is a medication used to treat non-small cell lung cancer and pancreatic cancer. Group: Pharmaceutical. Alternative Names: N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy-d3)-4-quinazolinamine Hydrochloride; 6,7-Bis(2-methoxyethoxy-d3)-4-(3-ethynylanilino)quinazoline Hydrochloride; [6,7-Bis(2-methoxyethoxy-d3)quinazolin-4-yl]-(3-ethynylphenyl)amine Hydrochloride; Erlotinib D6 Hydrochloride. CAS No. 1189953-78-3. Pack Sizes: 5 mg. Product ID: BLP-006076. Molecular formula: C22H18D6ClN3O4. Mole weight: 435.93. Custom synthesis is available. Send your inquiries for more information. | London |
| Erlotinib Impurity 8 | A metabolite of Erlotinib. Erlotinib is a tyrosine kinase inhibitor which acts on the epidermal growth factor receptor (EGFR), inhibiting EGFR-associated kinase activity. Group: Pharmaceutical. Alternative Names: N-(3-Desethynylphenyl)-N-(3-bromophenyl) Erlotinib; N-(3-bromophenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine. CAS No. 328528-74-1. Pack Sizes: 25 mg. Product ID: B2694-471125. Molecular formula: C20H22BrN3O4. Mole weight: 448.32. Custom synthesis is available. Send your inquiries for more information. | London |
| Ethyl (4-((2-(Methylcarbamoyl)pyridin-4-yl)oxy)phenyl)carbamate | An impurity of Sorafenib. Sorafenib is a small inhibitor of several tyrosine protein kinases, such as VEGFR, PDGFR and Raf family kinases, for the treatment of primary kidney cancer, advanced primary liver cancer and radioactive iodine resistant advanced thyroid carcinoma. Group: Pharmaceutical. Alternative Names: PAPE-ethyl Carbamate; Sorafenib related compound 7. CAS No. 2206827-12-3. Pack Sizes: 100 mg. Product ID: B2694-479756. Molecular formula: C16H17N3O4. Mole weight: 315.32. Custom synthesis is available. Send your inquiries for more information. | London |
| GDC-0853 | GDC-0853 is a Bruton's tyrosine kinase (BTK) inhibitor originated by Genentech. GDC-0853 can inhibit the activity of BTK and prevent the activation of the B-cell antigen receptor (BCR) signaling pathway. This leads to the inhibition of the growth of malignant B-cells that overexpress BTK. Phase III clinical trials for the treatment of Multiple sclerosis and Phase II clinical trials for the treatment of Chronic urticaria and Systemic lupus erythematosus are on-going. Uses: Rheumatoid arthritis; autoimmune disorders. Group: Pharmaceutical. Alternative Names: Fenebrutinib; RG 7845; RG7845; GDC0853; RG-7845; GDC 0853; (S)-2-(3'-(hydroxymethyl)-1-methyl-5-((5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-yl)amino)-6-oxo-1,6-dihydro-[3,4'-bipyridin]-2'-yl)-7,7-dimethyl-3,4,7,8-tetrahydro-2H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1(6H)-one. CAS No. 1434048-34-6. Pack Sizes: 100 mg. Product ID: B2693-475436. Molecular formula: C37H44N8O4. Mole weight: 664.81. Custom synthesis is available. Send your inquiries for more information. | London |
| Genistein | Genistein, a phytoestrogen found in soy products, is a highly specific inhibitor of protein tyrosine kinase (PTK) which blocks the mitogenic effect mediated by EGF on NIH-3T3 cells with IC50 of 12μM or by insulin with IC50 of 19 μM. Genistein is developed to be an antitumor agent. Genistein has antioxidant effect, it can be used in cosmetics material. It is a plant polyphenol that can inhibit tyrosinase, block melanin synthesis, reduce skin pigment intensity, absorb UV, prevent photoaging, reduce sun damage and age spot formation, and whiten and lighten spots. It also has the anti-glycation and antibacterial effect, can effectively improve skin tone and skin texture, prevent the generation of age spots, remove red bloodlines, and improve skin blood microcirculation. Uses: Antitumor agent. Group: Pharmaceutical. Alternative Names: 5,7-Dihydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; Baichanin A; Bonistein; 4',5,7-Trihydroxyisoflavone; GeniVida; Genisteol; NSC 36586; Prunetol; Sophoricol; Differenol A. CAS No. 446-72-0. Pack Sizes: 5 g. Product ID: BBF-01840. Molecular formula: C15H10O5. Mole weight: 270.24. Custom synthesis is available. Send your inquiries for more information. | London |
| Gilteritinib | Gilteritinib, also known as (ASP2215, is a potent FLT3/AXL inhibitor, which showed potent antileukemic activity against AML with either or both FLT3-ITD and FLT3-D835 mutations. In invitro, among the 78 tyrosine kinases tested, ASP2215 inhibited FLT3, LTK, ALK, and AXL kinases by over 50% at 1 nM with an IC50 value of 0.29 nM for FLT3, approximately 800-fold more potent than for c-KIT, the inhibition of which is linked to a potential risk of myelosuppression. ASP2215 inhibited the growth of MV4-11 cells, which harbor FLT3-ITD, with an IC50 value of 0.92 nM, accompanied with inhibition of pFLT3, pAKT, pSTAT5, pERK, and pS6. ASP2215 decreased tumor burden in bone marrow and prolonged the survival of mice intravenously transplanted with MV4-11 cells. ASP2215 may have potential use in treating AML. Group: Pharmaceutical. Alternative Names: ASP2215; ASP-2215; ASP 2215; Xospata; Gilteritinibum; 6-Ethyl-3-((3-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)-amino)-5-((tetrahydro-2H-pyran-4-yl)amino)pyrazine-2-carboxamide; 6-Ethyl-3-[[3-methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]amino]-5-[(tetrahydro-2H-pyran-4-yl)amino]-2-pyrazinecarboxamide. CAS No. 1254053-43-4. Pack Sizes: 100 mg. Product ID: B0084-462531. Molecular formula: C29H44N8O3. Mole weight: 552.71. Custom synthesis is available. Send your inquiries for more information. | London |
| Golvatinib | golvatinib (also known as E7050) is an orally bioavailable dual kinase inhibitor of c-Met (hepatocyte growth factor receptor) and VEGFR-2 (vascular endothelial growth factor receptor-2) tyrosine kinases with potential antineoplastic activity. c-Met/VEGFR kinase inhibitor E7050 binds to and inhibits the activities of both c-Met and VEGFR-2, which may inhibit tumor cell growth and survival of tumor cells that overexpress these receptor tyrosine kinases. c-Met and VEGFR-2 are upregulated in a variety of various tumor cell types and play important roles in tumor cell growth, migration and angiogenesis. Group: Pharmaceutical. Alternative Names: E7050; E-7050; E 7050; Golvatinib. CAS No. 928037-13-2. Pack Sizes: 50 mg. Product ID: B2693-460626. Molecular formula: C33H37F2N7O4. Mole weight: 633.701. Custom synthesis is available. Send your inquiries for more information. | London |
| Icotinib | Icotinib Hydrochloride (BPI-2009H), or Icotinib, is a highly selective, first generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). Group: Pharmaceutical. Alternative Names: BPI-2009H. CAS No. 610798-31-7. Pack Sizes: 300 mg. Product ID: B0084-459334. Molecular formula: C22H21N3O4. Mole weight: 391.42. Custom synthesis is available. Send your inquiries for more information. | London |
| Icotinib hydrochloride | Icotinib Hydrochloride is a quinazoline-based inhibitor of epidermal growth factor receptor (EGFR), which is upregulated in a variety of cancer cell types. Icotinib supresses the cancer cell proliferation via EGFR tyrosine kinase inhibition. Group: Pharmaceutical. Alternative Names: Icotinib HCl; BPI-2009; BPI 2009; BPI2009. CAS No. 1204313-51-8. Pack Sizes: 300 mg. Product ID: BBF-04036. Molecular formula: C22H22ClN3O4. Mole weight: 427.88. Custom synthesis is available. Send your inquiries for more information. | London |
| Imatinib-[d4] | Imatinib-[d4] is an isotopically labelled analogue of Imatinib. Imatinib is an inhibitor of multiple tyrosine kinases. It is a COVID-19-related research product. Group: Pharmaceutical. Alternative Names: N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide-2,3,5,6-d4; Imatinib D4. CAS No. 1134803-16-9. Pack Sizes: 5 mg. Product ID: BLP-005865. Molecular formula: C29H27D4N7O. Mole weight: 497.64. Custom synthesis is available. Send your inquiries for more information. | London |
| Imatinib EP Impurity D | An impurity of Imatinib, a tyrosine kinase inhibitor used as a chemotherapy drug for the treatment of leukemia and other kinds of cancer. Group: Pharmaceutical. Alternative Names: Des(methylpiperazinyl) Imatinib Dimer Piperazinium Chloride; 1-Methyl-1,4-bis[4-[(4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl)carbamoyl]benzyl]piperazin-1-ium chloride. CAS No. 1821122-73-9. Pack Sizes: 100 mg. Product ID: B2694-473167. Molecular formula: C53H51ClN12O2. Mole weight: 923.5. Custom synthesis is available. Send your inquiries for more information. | London |
| Imatinib EP Impurity J | An impurity of Imatinib, a tyrosine kinase receptor inhibitor used for cancer therapy. Group: Pharmaceutical. Alternative Names: Imatinib (Piperidine)-N-oxide; 4-[(4-Methyl-4-oxido-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide; CGP 71422; CGP71422; CGP-71422. CAS No. 571186-91-9. Pack Sizes: 10 mg. Product ID: B2694-473158. Molecular formula: C29H31N7O2. Mole weight: 509.62. Custom synthesis is available. Send your inquiries for more information. | London |
| Imatinib Guanidine Impurity | An impurity of Imatinib, a tyrosine kinase receptor inhibitor used for cancer therapy. Group: Pharmaceutical. Alternative Names: N-(3-Guanidino-4-methylphenyl)-4-(methylpiperazine-1-yl-methyl)benzamide; N-[3-[(Aminoiminomethyl)amino]-4-methylphenyl]-4-[(4-methyl-1-piperazinyl)methyl]benzamide; N-[2-Methyl-5-[[4-[(4-methylpiperazin-1-yl)methyl]benzoyl]amino]phenyl]guanidine. CAS No. 581076-65-5. Pack Sizes: 100 mg. Product ID: B2694-257315. Molecular formula: C21H28N6O. Mole weight: 380.5. Custom synthesis is available. Send your inquiries for more information. | London |
| Imatinib Impurity M | An impurity of Imatinib, a tyrosine kinase inhibitor used as a chemotherapy drug for the treatment of leukemia and other kinds of cancer. Group: Pharmaceutical. Alternative Names: 1,4-Bis(4-carboxybenzyl)-1-methylpiperazin-1-ium (Imatinib Impurity); 1,4-BIS(4-CARBOXYBENZYL)-1-METHYLPIPERAZIN-1-IUM; Imatinib Impurity M; SCHEMBL14646970; CS-0255288; F83280. CAS No. 1407229-73-5. Pack Sizes: 25 mg. Product ID: B2694-104820. Molecular formula: C21H25N2O4+. Mole weight: 369.44. Custom synthesis is available. Send your inquiries for more information. | London |
| Imatinib mesylate | Imatinib (INN), marketed by Novartis as Gleevec (Canada, South Africa and the USA) or Glivec (Australia, Europe and Latin America), and sometimes referred to by its investigational name STI-571, is a tyrosine-kinase inhibitor used in the treatment of multiple cancers, most notably Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML). Group: Pharmaceutical. Alternative Names: CGP-57148B; CGP 57148B; CGP57148B; Gleevec, Imatinib. CAS No. 220127-57-1. Pack Sizes: 10 g. Product ID: NP3279. Molecular formula: C29H31N7O.CH4SO3. Mole weight: 589.71. Custom synthesis is available. Send your inquiries for more information. | London |
| Imatinib Related Substance B | An impurity of Imatinib, a tyrosine kinase receptor inhibitor used for cancer therapy. Group: Pharmaceutical. Alternative Names: Imatinib (Piperidine)-N,N-dioxide; 4-[(4-Methyl-1,4-dioxido-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide. CAS No. 571186-93-1. Pack Sizes: 5 mg. Product ID: B2694-473161. Molecular formula: C29H31N7O3. Mole weight: 525.62. Custom synthesis is available. Send your inquiries for more information. | London |
| Irbinitinib | Irbinitinib,also known as ARRY-380 and ONT-380, is an orally bioavailable inhibitor of the human epidermal growth factor receptor tyrosine kinase ErbB-2 (also called HER2) with potential antineoplastic activity. ErbB-2 is overexpressed in a variety of cancers and plays an important role in cellular proliferation and differentiation. Uses: Antineoplastic agents. Group: Pharmaceutical. Alternative Names: ARRY-380; ARRY 380; ARRY380; ONT-380; ONT-380; ONT-380. CAS No. 937263-43-9. Pack Sizes: 100 mg. Product ID: B0084-462666. Molecular formula: C26H24N8O2. Mole weight: 480.532. Custom synthesis is available. Send your inquiries for more information. | London |
| JANEX-1 | A cell-permeable, reversible, potent, ATP-competitive, and specific inhibitor of JAK3 (Janus family kinase 3; IC50 = 78 μM). Has no effect on JAK1, JAK2, or Zap/Syk or Src tyrosine kinases. Acts as a potent inhibitor of glioblastoma cell adhesion and migration. Also reported to block thrombin-induced platelet aggregation. Group: Pharmaceutical. Alternative Names: WHI-P131, WHI P-131, WHI P131, Janex 1. CAS No. 202475-60-3. Pack Sizes: 50 mg. Product ID: B0084-211627. Molecular formula: C16H15N3O3. Mole weight: 297.31. Custom synthesis is available. Send your inquiries for more information. | London |
| JNJ-26483327 | JNJ-26483327 is an orally bioavailable, small-molecule, multitargeted reversible tyrosine kinase inhibitor with potential antineoplastic activity. Multitargeted tyrosine kinase inhibitor JNJ-26483327 binds to and inhibits several members of the epidermal growth factor receptor (EGFR) family, including EGFR, HER2 and HER4; Src family kinases (Lyn, Yes, Fyn, Lck and Src); and vascular endothelial growth factor receptor type 3 (VEGFR3). By inhibiting several different signaling molecules that play crucial roles at various stages in tumorigenesis, this agent may inhibit tumor growth, invasion, migration and metastasis. In addition, JNJ-26483327 crosses the blood-brain barrier (BBB). Group: Pharmaceutical. Alternative Names: JNJ-26483327; JNJ 26483327; JNJ26483327. CAS No. 807640-87-5. Pack Sizes: 10 mg. Product ID: B0084-462547. Molecular formula: C22H25BrN4O2. Mole weight: 457.372. Custom synthesis is available. Send your inquiries for more information. | London |
| Ki20227 | Ki-20227 is a highly selective c-Fms tyrosine kinase(CSF1R) inhibitor. Group: Pharmaceutical. Alternative Names: Ki20227; Ki 20227; Ki-20227. CAS No. 623142-96-1. Pack Sizes: 50 mg. Product ID: B0084-194510. Molecular formula: C24H24N4O5S. Mole weight: 480.54. Custom synthesis is available. Send your inquiries for more information. | London |
| KX2-391 | KX2-391 is an orally bioavailable small molecule Src kinase inhibitor with potential antineoplastic activity. Unlike other Src kinase inhibitors which bind to the ATP-binding site, Src kinase inhibitor KX2-391 specifically binds to the peptide substrate binding site of Src kinase; inhibition of kinase activity may result in the inhibition of primary tumor growth and the suppression of metastasis. Src tyrosine kinases are upregulated in many tumor cells and play important roles in tumor cell proliferation and metastasis. Uses: Enzyme inhibitors. Group: Pharmaceutical. Alternative Names: KX01, KX-01, KX 01, KX2-391; KX-2-391; KX 2-391; KX2391; KX-2391; KX 2391; Tirbanibulin. CAS No. 897016-82-9. Pack Sizes: 50 mg. Product ID: B2693-460303. Molecular formula: C26H29N3O3. Mole weight: 431.53. Custom synthesis is available. Send your inquiries for more information. | London |
| Lapatinib-[13C,d7] | Lapatinib-[13C,d7] is the labelled analogue of Lapatinib, a reversible dual inhibitor of ErbB1 and ErbB2 tyrosine kinases. It can be used for the treatment of breast cancer and other solid tumours. Group: Pharmaceutical. Alternative Names: Lapatinib-13C,D7; Lapatinib Ditosylate-13C,d7; Tykerb-13C,d7; GW 572016-13C,d7; Tyverb-13C,d7; N-{3-chloro-4-[(3-fluorophenyl)methoxy]phenyl}-6-[5-({[2-(13C,D3)methanesulfonyl(D4)ethyl]amino}methyl)furan-2-yl]quinazolin-4-amine. CAS No. 1210608-87-9. Pack Sizes: 1 mg. Product ID: BLP-011601. Molecular formula: C28[13C]H19D7ClFN4O4S. Mole weight: 589.09. Custom synthesis is available. Send your inquiries for more information. | London |
| Lavendustin A | Lavendustin A is an epidermal growth factor receptor inhibitor tyrosine kinase with IC50 value of 11 nM. Group: Pharmaceutical. Alternative Names: Lavendustin A; RG 14355; RG-14355; RG14355; 5-[[(2,5-Dihydroxyphenyl)methyl][(2-hydroxyphenyl)methyl]amino]-2-hydroxybenzoic acid. CAS No. 125697-92-9. Pack Sizes: 10 mg. Product ID: B0084-047820. Molecular formula: C21H19NO6. Mole weight: 381.38. Custom synthesis is available. Send your inquiries for more information. | London |
| Linifanib | Description of Linifanib: Linifanib is an orally bioavailable, small-molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Linifanib inhibits members of the vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) receptor families; it exhibits much less activity against unrelated RTKs, soluble tyrosine kinases, or serine/threonine kinases. This agent does not have a general antiproliferative effect due to its high dose requirement. However, linifanib may exhibit potent antiproliferative and apoptotic effects on tumor cells whose proliferation is dependent on mutant kinases, such as fms-related tyrosine kinase receptor-3 (FLT3). Group: Pharmaceutical. Alternative Names: ABT869; ABT 869; ABT-869; Linifanib. CAS No. 796967-16-3. Pack Sizes: 200 mg. Product ID: B0084-151820. Molecular formula: C21H18FN5O. Mole weight: 375.407. Custom synthesis is available. Send your inquiries for more information. | London |
| Masitinib | Masitinib is an orally bioavailable and multi-targeted protein tyrosine kinase inhibitor with potential antineoplastic activity. Group: Pharmaceutical. Alternative Names: AB-1010; AB 1010; AB1010; Masitinib. Brand name: Kinavet; Masivet. CAS No. 790299-79-5. Pack Sizes: 250 mg. Product ID: B0084-077384. Molecular formula: C28H30N6OS. Mole weight: 498.649. Custom synthesis is available. Send your inquiries for more information. | London |
| Methyl 1-Acetyl-2-oxoindoline-6-carboxylate | An impurity of Nintedanib, a receptor tyrosine kinase (RTK) inhibitor that binds to vascular endothelial growth factor receptor, fibroblast growth factor receptor and platelet derived growth factor receptor. Nintedanib is used as a medication for the treatment of idiopathic pulmonary fibrosis. Group: Pharmaceutical. Alternative Names: 1-acetyl-2-oxo-3H-indole-6-carboxylic acid methyl ester; methyl 1-acetyl-2-oxo-3H-indole-6-carboxylate. CAS No. 676326-36-6. Pack Sizes: 100 mg. Product ID: B1421-184191. Molecular formula: C12H11NO4. Mole weight: 233.22. Custom synthesis is available. Send your inquiries for more information. | London |
| MK-1775 | MK-1775, also known as AZD-1775, is a WEE1 inhibitor and a small-molecule inhibitor of the tyrosine kinase WEE1 with potential antineoplastic sensitizing activity. MK-1775 selectively targets and inhibits WEE1, a tyrosine kinase that phosphorylates cyclin-dependent kinase 1 (CDC2) to inactivate the CDC2/cyclin B complex. Inhibition of WEE1 activity prevents the phosphorylation of CDC2 and impairs the G2 DNA damage checkpoint. This may lead to apoptosis upon treatment with DNA damaging chemotherapeutic agents. Unlike normal cells, most p53-deficient or mutated human cancers lack the G1 checkpoint as p53 is the key regulator of the G1 checkpoint and these cells rely on the G2 checkpoint for DNA repair to damaged cells. Annulment of the G2 checkpoint may therefore make p53-deficient tumor cells more vulnerable to antineoplastic agents and enhance their cytotoxic effect. Group: Pharmaceutical. Alternative Names: MK-1775; MK1775; MK 1775; AZD1775; AZD-1775; AZD 1775; adavosertib. 1-[6-(2-hydroxypropan-2-yl)pyridin-2-yl]-6-[4-(4-methylpiperazin-1-yl)anilino]-2-prop-2-enylpyrazolo[3,4-d]pyrimidin-3-one. CAS No. 955365-80-7. Pack Sizes: 300 mg. Product ID: B0084-157422. Molecular formula: C27H32N8O2. Mole weight: 500.607. Custom synthesis is available. Send your inquiries for more information. | London |
| N-(2-Aminoethyl)-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide hydrochloride | One of the impurities of Sunitinib, which is a receptor tyrosine kinases inhibitor. Group: Pharmaceutical. Alternative Names: rac-Sunitinib Impurity G HCl; rac-N,N-Didesethyl Sunitinib Hydrochloride; rac-N,N-Didesethyl Sunitinib HCl; 1H-Pyrrole-3-carboxamide, N-(2-aminoethyl)-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, hydrochloride (1:1); N-(2-Aminoethyl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide hydrochloride. CAS No. 1217216-61-9. Pack Sizes: 10 mg. Product ID: B2694-482813. Molecular formula: C18H19FN4O2.HCl. Mole weight: 378.83. Custom synthesis is available. Send your inquiries for more information. | London |
| N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-2-butenamide | N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-2-butenamide is an impurity of Afatinib, which is a tyrosine kinase inhibitor used to treat non-small cell lung carcinoma (NSCLC). Uses: Antineoplastic agents. Group: Pharmaceutical. Alternative Names: 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-; (S)-N-(4-((3-chloro-4-fluorophenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide. CAS No. 439081-18-2. Pack Sizes: 500 mg. Product ID: B0084-092426. Molecular formula: C24H25ClFN5O3. Mole weight: 485.94. Custom synthesis is available. Send your inquiries for more information. | London |
| N-Desmethyl Imatinib | A metabolite of Imatinib, a tyrosine kinase receptor inhibitor used for cancer therapy. Group: Pharmaceutical. Alternative Names: N-[4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-(1-piperazinylmethyl)-benzamide; N-Desmethyl Gleevec. CAS No. 404844-02-6. Pack Sizes: 10 mg. Product ID: B2694-473156. Molecular formula: C28H29N7O. Mole weight: 479.59. Custom synthesis is available. Send your inquiries for more information. | London |
Our database is helping our users find suppliers everyday.
